Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ebru Pekguc"'
Autor:
Ebru Erdoğan, Koray Yalçın, Cansu Hemşinlioğlu, Aslıhan Sezgin, Utku Seyis, Derya Dilek Kancağı, Cihan Taştan, Bulut Yurtsever, Raife Dilek Turan, Didem Çakırsoy, Selen Abanuz, Gözde Sır Karakuş, Muhammer Elek, Hüseyin Saffet Beköz, Ali İhsan Gemici, Deniz Sargın, Mutlu Arat, Burhan Ferhanoğlu, Ebru Pekgüç, Serdar Örnek, Deram Büyüktaş, Nur Birgen, Siret Ratip, Ercüment Ovalı
Publikováno v:
Turkish Journal of Hematology, Vol 39, Iss 3, Pp 206-210 (2022)
Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability
Externí odkaz:
https://doaj.org/article/556bd673500c45ae8473e751960454e8
Autor:
Ebru Pekgüç, Burhan Ferhanoğlu
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S4- (2021)
Externí odkaz:
https://doaj.org/article/769556d6bb814e589b2e8127140082fe
Autor:
Mutlu Arat, Didem Cakirsoy, Selen Abanuz, Ercument Ovali, Bulut Yurtsever, Ali İhsan Gemici, Utku Seyis, Cansu Hemsinlioglu, Serdar Örnek, Gozde Sir Karakus, Huseyin Saffet Bekoz, Siret Ratip, Ebru Pekguc, Aslıhan Sezgin, Raife Dilek Turan, Koray Yalcin, Deniz Sargin, Muhammer Elek, Cihan Tastan, Deram Buyuktas, Burhan Ferhanoglu, Derya Dilek Kancagi, Nur Birgen, Ebru Erdogan
ObjectiveChimeric antigen receptor T (CAR-T) cell therapies already made an impact on the treatment of B cell malignancies. Although CAR-T cell therapies are promising, there are concerns with commercial products regarding their affordability and sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::572ac870518042265443af4f71a3838d
https://doi.org/10.1101/2021.09.23.21263731
https://doi.org/10.1101/2021.09.23.21263731
